SCHEMBL5834665

SCHEMBL5834665

Cc1ccc(O)c(NC(=O)c2cc([N+](=O)[O-])ccc2F)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.74
MEN1 O00255 5/20 0.74
SMN1; SMN2 Q16637 3/20 0.74
GAA P10253 2/20 0.74
MAPT P10636 4/20 0.61
KCNMA1 Q12791 7/20 0.58
POLB P06746 1/20 0.56
PABPC1 P11940 1/20 0.53
DUSP3 P51452 1/20 0.53
PTPN5 P54829 1/20 0.53
PTPN11 Q06124 1/20 0.53
EIF4H Q15056 1/20 0.53
CTDSP1 Q9GZU7 1/20 0.53
NPC1 O15118 2/20 0.52
RAB9A P51151 2/20 0.52
RORC P51449 2/20 0.52
PDPK1 O15530 2/20 0.51
ALDH1A1 P00352 2/20 0.51
AKT1 P31749 2/20 0.51
LMNA P02545 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5834857 0.90 KMT2A (0.74) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5834638 0.88 KCNMA1 (0.61) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5835259 0.86 KMT2A (0.65) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5835033 0.85 KCNMA1 (0.58) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5834919 0.85 MEN1 (0.63) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5834721 0.83 TMPRSS4 (0.61) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL7377697 0.81 RAB9A (0.68) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL8057912 0.81 KMT2A (0.64) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5834250 0.80 KCNMA1 (0.61) KMT2AMEN1SMN1; SMN2GAAMAPT
SCHEMBL5834318 0.79 RORC (0.54) KMT2AMEN1SMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7138425-B2 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2006-11-21 US disclosed
US-20050203153-A1 Phthalimide carboxylic acid derivatives OXFORD GLYCOSCIENCE (UK) LTD. (GB) 2005-09-15 US disclosed
EP-1483261-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden (GB) 2004-12-08 EP disclosed
WO-2003074516-A1 PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203153-A1 Phthalimide carboxylic acid derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HCCS, IDH1 KMT2A 1011/4885MEN1 693/4885SMN1; SMN2 3147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.